Radiotherapy Side Effect Clinical Trial
Official title:
Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05543239 -
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain
|
N/A | |
| Terminated |
NCT04535908 -
Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.
|
N/A | |
| Recruiting |
NCT04115267 -
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
|
||
| Recruiting |
NCT05820633 -
Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.
|
N/A | |
| Active, not recruiting |
NCT05880446 -
PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)
|
N/A | |
| Recruiting |
NCT05724004 -
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
|
N/A | |
| Recruiting |
NCT04612907 -
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
|
N/A | |
| Recruiting |
NCT05762900 -
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT03613506 -
The Role and Intervention of TGF-β in Abdominal Radiation Injury
|
Phase 2 | |
| Completed |
NCT06353724 -
Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent
|
N/A | |
| Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05224297 -
Patient Experience Data in Radiation Oncology
|
||
| Recruiting |
NCT05776147 -
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
|
||
| Completed |
NCT04842409 -
Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
|
||
| Recruiting |
NCT03742687 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
N/A | |
| Not yet recruiting |
NCT05614700 -
Prostate Reirradiation Toxicity Outcomes Feasibility Study
|
N/A | |
| Completed |
NCT04027543 -
Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）
|
||
| Recruiting |
NCT05354596 -
A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY).
|
N/A | |
| Recruiting |
NCT03378856 -
Evaluation of Technological Innovation in Radiotherapy
|